CLDN18 and neoplasm: Based on these results, the eligibility criteria in the phase 3 trial (SPOTLIGHT and GLOW trials) were CLDN18.2-positive patients defined as ≥75% of tumor cells with moderate-to-strong CLDN18 staining.